Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca adds to Zactima Phase III lung cancer program

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

AstraZeneca continues to pursue broad labeling for its oral targeted therapy Zactima (vandetanib) with a fourth Phase III trial in non-small cell lung cancer. The recently initiated trial, Study 36, will add data on another chemotherapy combination, with Lilly's Alimta (pemetrexed). An ongoing Phase III, Study 32, combines Zactima with Sanofi-Aventis' Taxotere (docetaxel), a combination that was also part of the Phase II program. AZ also tested single-agent Zactima in Phase II; ongoing Phase III Study 57 is evaluating monotherapy with Zactima or Genentech's Tarceva (erlotinib) in a head-to-head targeted therapy comparison in second- and third-line NSCLC. Another Phase III trial is enrolling in third- and fourth-line patients who have failed both chemotherapy and an EGFR inhibitor like Tarceva. The newest Phase III is expected to enroll 508 patients who failed at least one chemotherapy regimen; the first patient entered Study 36 in January 2007. Progression-free survival is the primary endpoint of Study 36...

You may also be interested in...



R&D In Brief

AtheroGenics AGI-1067 dose range restricted in Phase III due to liver concerns: The high-dose 300 mg arm of AtheroGenics' Phase III ANDES trial will be discontinued due to liver toxicity concerns, the company announces Nov. 9. Additional analysis of an earlier Phase III study, ARISE, found rare adverse effects on the liver with a 300 mg dose of the oral anti-inflammatory antioxidant AGI-1067. ANDES was designed to elucidate subgroup effects seen in diabetic patients enrolled in ARISE, a pivotal atherosclerosis trial that failed to meet its primary cardiovascular event endpoint. AtheroGenics and then-partner AstraZeneca had hoped ARISE would support multiple claims for AGI-1067 in subgroups. After the stumble with ARISE, AtheroGenics shifted its focus for AGI-1067 from atherosclerosis to glycemic control in type 2 diabetes. ANDES started enrolling diabetes patients in August as a dose-ranging trial to confirm the ARISE diabetes findings. The trial will continue with the two lower-dose arms (75 and 150 mg); an interim analysis is planned for the second quarter of 2008...

Biden Extends Helping Hand To Small US Manufacturers, Vendors With ‘Made In America’ EO

The president’s executive order aims to give smaller companies a leg up over foreign competitors, among other objectives.

Warning Letter Roundup & Recap – 26 January 2021

No device-related warning letters were released by the US FDA the week of 26 January.

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel